Top

Published in:

01-05-2022 | Thyroid Cancer | Research Letter

Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer

Authors: Mohamed A. Gouda, Emily Ong, Helen J. Huang, Laron W. McPhaul, Steve Yoon, Filip Janku, Andrew G. Gianoukakis

Published in: Endocrine | Issue 2/2022

Excerpt

There has been a growing interest in characterizing molecular alterations that can drive oncogenesis in thyroid cancer [1]. These molecular alterations are increasingly gaining importance in diagnosis and prognostication and can represent targets for therapeutic intervention. Some of the most studied actionable mutations are BRAF alterations, which are present in 30–70% of patients [2‐4]. These alterations lead to unbridled activation of the MAPK pathway which controls cell growth and division, thus contributing to thyroid cancer pathogenesis [1, 3, 5‐9]. …

Available only for authorised users

M. Xing, Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer 13, 184–199 (2013)CrossRef

A. Zaman, W. Wu, T.G. Bivona, Bivona, Targeting oncogenic BRAF: past, present, and future. Cancers 11, 1197 (2019).CrossRef

M. Xing, A.S. Alzahrani, K.A. Carson, D. Viola, R. Elisei et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309, 1493–1501 (2013)CrossRef

A. Czarniecka, M. Oczko-Wojciechowska, M. Barczynski, BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg. 5, 495–505 (2016)CrossRef

L.R.Q. Barreno, J.B.H. Mello, M.C. Barros-Filho, A.L. Francisco, T.C. Chulam et al. Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma. Braz. J. Otorhinolaryngol. (2020). https://www.sciencedirect.com/science/article/pii/S1808869420301373?via%3Dihub. Online ahead of print

M.J. Garnett, R. Marais, Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313–319 (2004)CrossRef

P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004)CrossRef

E.T. Kimura, M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454–1457 (2003)PubMed

J. Ge, J. Wang, H. Wang, X. Jiang, Q. Liao et al. The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. J. Cancer 11, 932–939 (2020)CrossRef

10.

M. Gerlinger, A.J. Rowan, S. Horswell, M. Math, J. Larkin et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012)CrossRef

11.

C. Bettegowda, M. Sausen, R.J. Leary, I. Kinde, Y. Wang et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014)CrossRef

12.

C. Rolfo, P.C. Mack, G.V. Scagliotti, P. Baas, F. Barlesi et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J. Thorac. Oncol. 13, 1248–1268 (2018)CrossRef

13.

M. Daniotti, V. Vallacchi, L. Rivoltini, R. Patuzzo, M. Santinami et al. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J. Cancer 120, 2439–2444 (2007)CrossRef

14.

K.W. Cradic, D. Milosevic, A.M. Rosenberg, L.A. Erickson, B. McIver et al. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J. Clin. Endocrinol. Metab. 94, 5001–5009 (2009)CrossRef

15.

J.Y. Kwak, J.J. Jeong, S.W. Kang, S. Park, J.R. Choi et al. Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas. Head. Neck 35, 1630–1633 (2013)CrossRef

16.

V. Condello, E. Macerola, C. Ugolini, L. De Napoli, C. Romei et al. Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma. Head. Neck 40, 1752–1758 (2018)PubMed

17.

B.H. Kim, I.J. Kim, B.J. Lee, J.C. Lee, I.S. Kim et al. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas. Yonsei Med. J. 56, 634–640 (2015)CrossRef

18.

J.M. Fussey, J.L. Bryant, N. Batis, R.J. Spruce, A. Hartley et al. The clinical utility of cell-free DNA measurement in differentiated thyroid cancer: a systematic review. Front Oncol. 8, 132 (2018)CrossRef

19.

D.M. Allin, R. Shaikh, P. Carter, K. Thway, M.T.A. Sharabiani et al. Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. Eur. J. Cancer 103, 165–175 (2018)CrossRef

20.

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)CrossRef

21.

C.P. Gilfillan, Review of the genetics of thyroid tumours: diagnostic and prognostic implications. ANZ J. Surg. 80, 33–40 (2010)CrossRef

Title: Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer
Authors: Mohamed A. Gouda
Emily Ong
Helen J. Huang
Laron W. McPhaul
Steve Yoon
Filip Janku
Andrew G. Gianoukakis
Publication date: 01-05-2022
Publisher: Springer US
Keywords: Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Published in: Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-022-03004-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2022

Clinicopathologic features and lymph node metastasis pattern of the cervical MiNEN

Salvage total thyroidectomy for amiodarone-induced thyrotoxicosis in a SARS-CoV-2 positive patient: results of the viral genome research on the pathology sample of this destructive thyroiditis

Maternal serum leptin in the pregnant rat: fetal-placental implantation number and progesterone

ROC-curves—fundamentals for proper use

Characterization of vitamin D metabolism in active acromegaly in the setting of bolus (150,000 IU) cholecalciferol treatment

Granular cell tumor of thyroid: a case series with molecular characterization highlighting unique pitfalls

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page